

# Vaccine Effectiveness or Vaccine Coverage: What Matters Most for Influenza Outcomes in Australia?

**Date:** Tuesday 16th June 2026  
**Time:** 7:15am (Registration from 7:00am)  
**Venue:** Foundry Room (Level 2), Marvel Stadium *Breakfast will be provided*

## Expert Panel

<b>Dr. Jessica Miller</b> Epidemiologist, VIC	<b>Prof. Catherine Bennett</b> Epidemiologist, VIC
<b>Ms. Angela Newbound</b> Registered Nurse & Immunisation Education Consultant, SA	<b>Dr. Sarah Chu</b> Specialist General Practitioner, QLD

Influenza continues to pose a substantial burden on Australia's health system, particularly among older adults.<sup>1-6</sup> While vaccination remains the cornerstone of prevention,<sup>3</sup> enduring and timely questions remain: is it vaccine effectiveness or vaccine coverage that most strongly determines real world influenza outcomes? And is it possible to achieve both?

This interactive satellite breakfast symposium will bring together leading Australian experts to explore this question from varying perspectives. Through focused presentations, delegates will gain insights into the population level impact of vaccine effectiveness and the critical role of achieving and sustaining high vaccination coverage – especially in the context of an ageing population, post-pandemic vaccine hesitancy and broader systemic trust.


Designed to provoke reflection and discussion, delegates will be invited to share their own experiences and viewpoints enabling a rich exchange between policy makers, program managers, clinicians and researchers. In the context of the successful adult influenza vaccination program attendees will be invited to consider what defines “standard of care” in influenza prevention – and what expectations we should hold for future innovations.

**Join us and a panel of experts for breakfast** and a dynamic, thought provoking discussion on shaping the next chapter and advancing the standard of care for influenza prevention in Australia.



**For questions,  
please contact:**


[Erin.Matthews@seqirus.com](mailto:Erin.Matthews@seqirus.com)



**SCAN TO REGISTER**

# Vaccine Effectiveness or Vaccine Coverage: What Matters Most for Influenza Outcomes in Australia?

Time	Topic	Speaker
7:00 – 7:15 am	Registration	
7:15 – 7:20 am	Welcome & Introduction	Dr. Jessica Miller
7:20 – 7:30 am	Effectiveness-first strategies	Prof. Catherine Bennett
7:30 – 7:40 am	Coverage as a core outcome	Ms. Angela Newbound
7:40 – 8:20 am	Interactive discussion & workshop	<b>Facilitator:</b> Mr. Daniel Yu
8:20 – 8:30 am	A real-world example: FLUAD® Inactivated Trivalent Influenza Vaccine (Surface Antigen), Adjuvanted	Dr. Sarah Chu
8:30 – 8:45 am	Panel Q&A	<b>Facilitator:</b> Dr. Jessica Miller
8:45 am	Close	



**For questions,  
please contact:**

[Erin.Matthews@seqirus.com](mailto:Erin.Matthews@seqirus.com)

**SCAN TO REGISTER**

**FLUAD® PBS Information:** This product is listed on the National Immunisation Program (NIP) for people 65+ years. Refer to NIP Schedule.



Please review the relevant full Product Information (PI) before prescribing. Full PI is available via the QR code:

**References:** **1.** National Foundation for Infectious Disease. Influenza and older adults. Available at: <https://www.nfid.org/infectious-diseases/flu-and-older-adults>. Accessed June 2026. **2.** Moa AM *et al.* Influenza Other Respi Viruses 2022; 16:132-141. **3.** Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook, Australian Government Department of Health and Aged Care, Canberra, 2024, [immunisationhandbook.health.gov.au](https://immunisationhandbook.health.gov.au). Accessed June 2026. **4.** Newall AT *et al.* Vaccine 2008; 26; 2135-41. **5.** Marchi S, *et al.* Hum Vaccin Immunother. 2023;19(2):2257048. **6.** Kim P, *et al.* Open Forum Infect Dis. 2023. Jan; 10(1):ofac664.

**CSL Seqirus**